Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lung Diseases, Interstitial

ClinicalTrials.gov lists 1,623 trials for Lung Diseases, Interstitial or a narrower condition beneath it. Boehringer Ingelheim has the most among industry and government lead sponsors, with 67.

MeSH D017563 Respiratory Tract Diseases C08 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 160 Phase 1/2 Phase 1/2 43 Phase 2 Phase 2 318 Phase 2/3 Phase 2/3 36 Phase 3 Phase 3 123 Phase 4 Phase 4 64 Not applicable Not applicable 305 Observational Observational 565 Phase 1 Phase 1 160 Phase 1/2 Phase 1/2 43 Phase 2 Phase 2 318 Phase 2/3 Phase 2/3 36 Phase 3 Phase 3 123 Phase 4 Phase 4 64 Not applicable Not applicable 305 Observational Observational 565

Trials per phase

1 more section with rows

636 of the 1,623 trials are tagged with Lung Diseases, Interstitial itself; the rest are tagged with a narrower condition beneath it.

Get the Lung Diseases, Interstitial report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lung Diseases, Interstitial trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 136

1990: 1 trials (Phase 2 1) 1995: 5 trials (Observational 2, Phase 2/3 1, Phase 2 1, Phase 1 1) 1996: 4 trials (Observational 4) 1997: 1 trials (Observational 1) 1998: 3 trials (Phase 2/3 1, Phase 1 2) 1999: 7 trials (Observational 3, Phase 3 2, Phase 2 2) 2000: 10 trials (Observational 1, Not applicable 2, Phase 3 3, Phase 2/3 2, Phase 2 2) 2001: 5 trials (Observational 2, Phase 2 3) 2002: 4 trials (Phase 3 1, Phase 2 3) 2003: 19 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 3, Phase 2 5, Phase 1/2 1, Phase 1 2) 2004: 9 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1 1) 2005: 19 trials (Observational 9, Not applicable 2, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2006: 17 trials (Observational 9, Phase 4 1, Phase 3 3, Phase 2 3, Phase 1/2 1) 2007: 25 trials (Observational 7, Not applicable 3, Phase 4 2, Phase 3 4, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2008: 23 trials (Observational 7, Not applicable 1, Phase 4 2, Phase 3 6, Phase 2 5, Phase 1/2 1, Phase 1 1) 2009: 21 trials (Observational 7, Not applicable 1, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1 2) 2010: 36 trials (Observational 17, Not applicable 6, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 4) 2011: 43 trials (Observational 16, Not applicable 3, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 2) 2012: 41 trials (Observational 19, Not applicable 9, Phase 3 3, Phase 2 7, Phase 1/2 1, Phase 1 2) 2013: 53 trials (Observational 19, Not applicable 8, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 11, Phase 1/2 3, Phase 1 5) 2014: 51 trials (Observational 16, Not applicable 10, Phase 4 6, Phase 3 2, Phase 2/3 3, Phase 2 9, Phase 1/2 4, Phase 1 1) 2015: 66 trials (Observational 25, Not applicable 9, Phase 4 4, Phase 3 5, Phase 2/3 1, Phase 2 13, Phase 1/2 1, Phase 1 8) 2016: 68 trials (Observational 27, Not applicable 10, Phase 4 6, Phase 3 4, Phase 2/3 3, Phase 2 11, Phase 1/2 1, Phase 1 6) 2017: 80 trials (Observational 29, Not applicable 19, Phase 4 2, Phase 3 7, Phase 2/3 2, Phase 2 16, Phase 1/2 1, Phase 1 4) 2018: 86 trials (Observational 32, Not applicable 23, Phase 4 3, Phase 3 3, Phase 2/3 1, Phase 2 17, Phase 1/2 1, Phase 1 6) 2019: 77 trials (Observational 26, Not applicable 19, Phase 4 3, Phase 3 3, Phase 2 16, Phase 1/2 2, Phase 1 8) 2020: 113 trials (Observational 47, Not applicable 18, Phase 4 7, Phase 3 5, Phase 2 21, Phase 1/2 3, Phase 1 12) 2021: 111 trials (Observational 42, Not applicable 22, Phase 4 3, Phase 3 7, Phase 2/3 2, Phase 2 16, Phase 1/2 2, Phase 1 17) 2022: 105 trials (Observational 39, Not applicable 19, Phase 4 3, Phase 3 12, Phase 2/3 1, Phase 2 18, Phase 1/2 2, Phase 1 11) 2023: 136 trials (Observational 45, Not applicable 35, Phase 4 2, Phase 3 6, Phase 2/3 4, Phase 2 20, Phase 1/2 5, Phase 1 19) 2024: 122 trials (Observational 39, Not applicable 28, Phase 4 4, Phase 3 3, Phase 2/3 2, Phase 2 26, Phase 1/2 4, Phase 1 16) 2025: 105 trials (Observational 33, Not applicable 19, Phase 4 1, Phase 3 6, Phase 2 29, Phase 1/2 3, Phase 1 14)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 131
2025 105
2024 122
2023 136
2022 105
2021 111
2020 113
2019 77
2018 86
2017 80

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 140 trials starting in 2026 and about 130 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 190 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 846 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lung Diseases, Interstitial trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 160
Phase 1/2 43
Phase 2 318
Phase 2/3 36
Phase 3 123
Phase 4 64
Not applicable 305
Observational 565
Expanded access 9

How many Lung Diseases, Interstitial trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 87
Recruiting 271
Enrolling by invitation 16
Active, not recruiting 96
Available 4

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lung Diseases, Interstitial trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Boehringer Ingelheim 67
Hoffmann-La Roche 19
National Heart, Lung, and Blood Institute (NHLBI) 18
National Cancer Institute (NCI) 15
National Institute of Allergy and Infectious Diseases (NIAID) 14

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Lung Diseases, Interstitial? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 32
Cytoxan 23
Prednisone 17
SILDENAFIL 10
BI 1015550 10

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Pirfenidoneone 62
L01XE31 - Nintedanib 57
Mofetil Mycophenolate 14
HD- Methotrexate (MTX) 9
Glucocorticoids 8

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lung Diseases, Interstitial trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Idiopathic pulmonary fibrosis 2,686 65
Pneumonia 1,414 88
Respiratory failure 562 66
Dyspnoea 480 64
Pneumothorax 407 52

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lung Diseases, Interstitial? (641)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Comprehensive characterisation of individuals with fibrotic interstitial lung disease: baseline insights from the INJUSTIS study. BMJ open respiratory research 2026 Yes
A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts. Respiratory research 2025 Yes
An App Platform-Facilitated Collaborative Palliative Care Intervention for Outpatients With Interstitial Lung Disease: A Pilot Randomized Trial. The American journal of hospice & palliative care 2025 Yes
Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease. Rheumatology (Oxford, England) 2025 Yes
Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot study. Respirology (Carlton, Vic.) 2025 Yes

Showing 5 of 641 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (15)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Interstitial lung disease Point prevalence 1-5 / 10 000 Greece Not stated Unspecified
Interstitial lung disease Annual incidence 1-9 / 100 000 Denmark Not stated Exact
Interstitial lung disease Annual incidence 1-9 / 100 000 Europe Not stated Exact
Interstitial lung disease Annual incidence 1-9 / 100 000 Spain Not stated Exact
Interstitial lung disease Annual incidence 1-9 / 100 000 Denmark Not stated Exact

Showing 5 of 15 prevalence observations.

Start your 14-day trial Email me all 15 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Interstitial lung disease 182095 Exact Orphadata Science knowledge files, Product 1
Interstitial lung disease 182095 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages